FBIO vs. BOLT, MTEM, BCTX, IPA, SPRB, MRKR, APLM, PMN, VIRX, and CASI
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), BriaCell Therapeutics (BCTX), ImmunoPrecise Antibodies (IPA), Spruce Biosciences (SPRB), Marker Therapeutics (MRKR), Apollomics (APLM), ProMIS Neurosciences (PMN), Viracta Therapeutics (VIRX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical preparations" industry.
Bolt Biotherapeutics (NASDAQ:BOLT) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 28.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Bolt Biotherapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 530.63%. Fortress Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,634.10%. Given Bolt Biotherapeutics' higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.
Fortress Biotech has a net margin of -74.12% compared to Fortress Biotech's net margin of -878.58%. Fortress Biotech's return on equity of -51.18% beat Bolt Biotherapeutics' return on equity.
Fortress Biotech received 243 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 64.86% of users gave Fortress Biotech an outperform vote.
In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Bolt Biotherapeutics and 1 mentions for Fortress Biotech. Bolt Biotherapeutics' average media sentiment score of 0.00 beat Fortress Biotech's score of -0.33 indicating that Fortress Biotech is being referred to more favorably in the news media.
Bolt Biotherapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.
Summary
Fortress Biotech beats Bolt Biotherapeutics on 12 of the 17 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
